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To the Editor,  
 
We thank Dr. Newman and colleagues for their careful reading of our manuscript and for their 
additional recommendations.   
 
We agree that creating a single set of guidelines covering the multitude of systemic and 
neurological manifestations of mitochondrial diseases is difficult, and that the 
recommendations will inherently not apply to every situation or every patient. However, the 
Delphi methodology we used allowed us to synthesize what were sometimes diverse views, and 
thereby to present a consensus based on the experience of a panel of mitochondrial disease 
physicians. This approach has been shown to be most valuable when there is limited objective 
evidence base, as for mitochondrial disorders.   
 
In regard to the concern of whether a neuro-ophthalmologist is required for routine care of 
these patients, the writing group considered that such a specialist, if accessible by the patient, 
would be the ideal physician to monitor the ophthalmological manifestations of the disease. A 
neuro-ophthalmologist would also be the best person to determine the need for subspecialty 
ophthalmology referrals.  It is important to note that this was only a recommendation, and not 
considered to be essential for each and every patient.  
 
With regard to the monitoring of intraocular pressure, while it should be an integral part of 
every general eye exam, some members of the consortium have noted that this portion of the 
examination is not always performed in some pediatric patients. For this reason, an additional 
statement was included to recommend this testing be done when necessary.  
 
We agree that lubrication is required to prevent the keratopathy that occurs with corneal 
exposure in some mitochondrial patients, and not only due to the inappropriate spread of 
tears.  We also agree that it would be wise for affected and unaffected LHON mtDNA mutation 
carriers to avoid cigarette smoking and excessive alcohol use, although the evidence that well-
established LHON deteriorates with smoking or excess alcohol is limited. The seventh 
recommendation was included to alert the clinician to the presence of LHON plus phenotypes, 
with some authors feeling that a periodic neurologic exam may detect pre-clinical symptoms, 
and a follow-up electrocardiogram may detect a pre-excitation syndrome not apparent on the 
first examination.  
 
It is important to stress that our recommendations were not a universal view held by all of the 
authors and rather a consensus statement reflecting the majority. This approach has both 
strengths and weaknesses. Inevitably this means that the outcome of the review was 
dependent on the authors who engaged the process. To address this, we did make an open 
invitation to interested clinician-members of the Mitochondrial Medicine Society to participate. 
However, most importantly, the consensus describes a ‘current state of play’, which definitely 
should be revised as additional objective information comes to hand.  
 
We therefore welcome their additional comments, and look forward to incorporating these 
suggestions in any future revised version of the criteria. 
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